|
Canada Communicable Disease Report
Vol. 25 (ACS-1)
1 May 1999
An Advisory Committee Statement (ACS)
National Advisory Committee on Immunization (NACI)
STATEMENT ON RECOMMENDED USE OF VARICELLA VIRUS VACCINE
Adobe Downloadable Document
(480 KB)
Table 1 Age-related severity of varicella as indicated
by frequency and severity of rash and fever relative to prior receipt
of live-attenuated varicella vaccine, clinical syndrome, prior health,
and age
|
Varicella vaccination history,
clinical illness, prior health,
and age
|
Variation in rash formation and number of lesions
(Number of lesions expressed as median or mean [range])
|
Fever
|
|
Generalized Rash
|
Injection Site Rash
|
|
New lesion formation* (days)
|
Frequency (%) after:
|
Number (range) of lesions
|
Frequency (%) after:
|
Number (range) of lesions
|
Frequency (%) after:
|
|
Dose 1
|
Dose 2
|
Dose 1
|
Dose 2
|
Dose 1
|
Dose 2
|
|
NO PRIOR VACCINE
Acute Varicella
Otherwise healthy
|
|
2-12 years(3)
|
3.4
|
|
|
347
|
|
|
|
67
|
|
|
13-18 years(4)
|
3.2
|
|
|
421
|
|
|
|
62
|
|
|
Adults(5)
|
3.9
|
|
|
500+
|
|
|
|
80
|
|
|
Immunocompromised
Children with cancer(6)
|
7 (2-14)
|
|
|
500+
|
|
|
|
|
|
|
PRIOR VACCINE
Varicella-related rash within 0-42 days
Otherwise healthy
|
|
1-17 years(15-17)
|
|
4-5
|
0
|
11 (1-100)
|
3-6
|
0
|
3 (1-22)
|
2-5
|
|
|
Adults(18,19)
|
|
5-10
|
0.9
|
14 (1-100)
|
3
|
1
|
2
|
10.2
|
9.5
|
|
Children with ALL**, remission > 1 year(20)
|
|
|
|
|
|
|
|
|
|
|
On chemotherapy
|
|
42
|
< 10
|
|
|
|
|
10
|
3-5
|
|
Off chemotherapy
|
|
6
|
< 10
|
|
|
|
|
10
|
3-5
|
|
Acute varicella > 42 days after vaccine
Otherwise healthy
|
|
1-17 years(21)
|
|
|
|
36 (1-250)
|
|
|
|
28
|
|
|
Adults(18)
|
|
|
|
31 (1-100)
|
|
|
|
25
|
|
|
Children with ALL, remission > 1 year(22)
|
|
|
|
100 (3-400)
|
|
|
|
59
|
|
|
(27 cases, 0 given VZIG prophylaxis,
2 treated with acyclovir)
|
|
|
|
|
|
|
|
|
|
|
* Time period from onset until eruption of the new lesions ceases.
** ALL = Acute lymphoblastic leukemia
|
[Canada Communicable
Disease Report]
|
